Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

24.22 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,063
Open 24.22
Bid (Size) 23.10 (500)
Ask (Size) 25.30 (200)
Prev. Close 24.22
Today's Range 24.22 - 24.22
52wk Range 13.53 - 36.44
Shares Outstanding 79,199,501
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
From Beam Therapeutics
Via GlobeNewswire

Performance

YTD
-10.8%
-10.8%
1 Month
-15.6%
-15.6%
3 Month
-12.6%
-12.6%
6 Month
+0.4%
+0.4%
1 Year
+37.3%
+37.3%

More News

Read More
News headline image
What's Going On With Beam Therapeutics Stock? ↗
Via Benzinga
News headline image
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
From Beam Therapeutics
Via GlobeNewswire
BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise ↗
Via Stocktwits
News headline image
Is Beam Therapeutics Gaining or Losing Market Support? ↗
Via Benzinga
News headline image
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Government
Top stock movements in today's session. ↗
Via Chartmill
News headline image
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
From Beam Therapeutics
Via GlobeNewswire
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics (BEAM) Earnings Transcript ↗
Via The Motley Fool
Topics Death
News headline image
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
Via TokenRing AI
Topics Artificial Intelligence Climate Change Intellectual Property
News headline image
Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys ↗
Via Benzinga
News headline image
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
News headline image
WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
Jefferies Initiates Beam Therapeutics with "Buy" Rating, Eyeing Promising Gene-Editing Pipeline and Upcoming Catalysts
Via MarketMinute
News headline image
Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
Via MarketMinute
Topics Artificial Intelligence Climate Change Economy

Frequently Asked Questions

Is Beam Therapeutics Inc. - Common Stock publicly traded?
Yes, Beam Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Beam Therapeutics Inc. - Common Stock trade on?
Beam Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Beam Therapeutics Inc. - Common Stock?
The ticker symbol for Beam Therapeutics Inc. - Common Stock is BEAM on the Nasdaq Stock Market
What is the current price of Beam Therapeutics Inc. - Common Stock?
The current price of Beam Therapeutics Inc. - Common Stock is 24.22
When was Beam Therapeutics Inc. - Common Stock last traded?
The last trade of Beam Therapeutics Inc. - Common Stock was at 04/01/26 04:00 PM ET
What is the market capitalization of Beam Therapeutics Inc. - Common Stock?
The market capitalization of Beam Therapeutics Inc. - Common Stock is 1.92B
How many shares of Beam Therapeutics Inc. - Common Stock are outstanding?
Beam Therapeutics Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.